Q&A

Expansion Into New Modalities — During The Pandemic And Beyond

Source: Rentschler Biopharma
iStock-1222894162-vaccine-lab-PPE

Supporting both German mRNA-based COVID-19 vaccine developers BioNTech SE and CureVac N.V., Rentschler Biopharma SE has not only expanded into the promising field of RNA manufacturing. In this interview, Federico Pollano, Senior Vice President, Global Business Development, speaks about the company’s recent expansion into the cell and gene therapy market.

VIEW THE Q&A!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Rentschler Biopharma